Background: Tofacitinib is an oral Janus kinase inhibitor. Efficacy and safety of tofacitinib in patients with moderate-to-severe plaque psoriasis have been demonstrated.
It is estimated that approximately 40% to 50% of patients with psoriasis are affected by nail psoriasis, with a lifetime incidence of 80% to 90%. [1] [2] [3] Nail psoriasis involves inflammation at the nail unit and manifests with pitting, onycholysis, discoloration, subungual hyperkeratosis, and splinter hemorrhages, which can lead to structural and functional impairment. 2, 4 Although nails account for a small proportion of the body surface area, they can have a substantial effect on a patient's quality of life. 5, 6 Higher disease severity and greater impairment of healthrelated quality of life (HRQoL) have been reported among patients with nail psoriasis compared with patients with psoriasis who do not have nail involvement. 1, [5] [6] [7] Data from [2000 patients with psoriasis who participated in the PsoReal epidemiology study in Germany showed that those with nail involvement had significantly greater affected body surface area (8.3% vs 5.6%; P \ .004), lower HRQoL, and more days absent from work. 7 In addition, the presence of nail psoriasis may be associated with a higher risk of developing psoriatic arthritis (PsA). 8, 9 A meta-analysis of data from 25 clinical studies reported an odds ratio of 2.92 (95% confidence interval: 2.34, 3.64) for the association between nail involvement in psoriasis, particularly onycholysis, and risk of PsA. 9 Nail psoriasis can involve the nail bed and nail matrix. Psoriasis involving the nail matrix is more difficult to manage because, although topical therapeutics can be applied to the nail bed, they cannot penetrate into the matrix. 10 Intralesional steroids are often used for matrix involvement, but administration can be painful to the patient. 10 Current treatment options include topical corticosteroids, vitamin A and D analogs, and intralesional therapies, with systemic therapies and biologics recommended for patients with inadequate response or significant cutaneous involvement. 2, 10 However, there is little clinical evidence to support these recommended approaches.
Tofacitinib is an oral Janus kinase (JAK) inhibitor. The efficacy and tolerability of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis have previously been demonstrated in 4 phase 3 studies. [11] [12] [13] Here, we report the results of a post hoc analysis of data from 2 of these phase 3 studies, OPT Pivotal 1 and OPT Pivotal 2, to evaluate changes in nail psoriasis with tofacitinib treatment over a period of 52 weeks in patients with existing nail psoriasis at baseline. No data on nail psoriasis were collected from the 2 other phase 3 studies of tofacitinib for psoriasis, and therefore these studies could not be included in this analysis.
METHODS

Study design and patients
This was a post hoc analysis of pooled data from 2 52-week, multisite, randomized, double-blind, phase 3 studies with identical designs, OPT Pivotal 1 (NCT01276639) and OPT Pivotal 2 (NCT01309737). 13 Eligible patients were adults with a diagnosis of plaque psoriasis for $12 months prior to the first dose of study drug, baseline Psoriasis Area and Severity Index (PASI) score $12, Physician's Global Assessment (PGA) of moderate or severe, and $10% affected body surface area at baseline. Patients with nonplaque forms of psoriasis, recent systemic or local infection, and current malignancy or history of malignancies (except for adequately treated or excised basal/squamous cell carcinoma or cervical carcinoma in situ) were excluded. Patients were required to discontinue active psoriatic treatments (topical, systemic, and phototherapy) and immunosuppressive therapy prior to being enrolled in the study, with minimum washout periods as specified in the study protocols.
Patients were randomized 2:2:1 to receive tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, or placebo twice daily. At week 16, placebo patients were re-randomized to tofacitinib 5 mg or 10 mg twice daily. At week 28, patients who had not achieved either $75% reduction from baseline in the PASI score or a PGA of ''clear'' or ''almost clear'' were withdrawn from the study. Tofacitinib treatment was continued up to week 52 for patients remaining in the study.
Both studies were conducted in compliance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice Guidelines and were approved by the institutional review boards and/or independent ethics committees at each investigational center. All patients provided written informed consent.
CAPSULE SUMMARY d
Tofacitinib is an oral Janus kinase inhibitor; previous studies have shown that tofacitinib treatment improves moderate-to-severe plaque psoriasis. This study demonstrated improvement in nail psoriasis with tofacitinib versus placebo at week 16, which was maintained through week 52. Oral tofacitinib is a potentially useful agent for nail psoriasis.
Assessments and outcomes
Nail psoriasis was assessed at baseline and at weeks 8, 16, 20, 28, 40, and 52, using the Nail Psoriasis Severity Index (NAPSI).
14 Each fingernail was divided into 4 quadrants, and each quadrant was assessed for the presence of psoriatic nail manifestations in both the nail matrix and the nail bed, giving a score out of 8 for each nail. Total NAPSI scores were calculated as the sum of scores for all fingernails and ranged from 0 (no affected nails) to 80 (both nail matrix and bed of all quadrants of all nails affected). The proportion of patients achieving a 50%, 75%, and 100% (complete clearance) reduction from baseline in NAPSI score (NAPSI50, NAPSI75, and NAPSI100) and the change in NAPSI score from baseline were calculated for each assessment.
Statistical analyses
Data from the 2 studies were pooled, and post hoc analyses were performed on the subset of patients from the full analysis set (FAS) with nail psoriasis at baseline. The FAS comprised all randomized patients who received $1 dose of study medication. Differences between treatment groups in the proportion of patients achieving NAPSI50, NAPSI75, and NAPSI100 at week 16 were compared by means of normal approximation of binary variables. Nonresponder imputation was applied to missing data. Least-squares (LS) mean changes from baseline in NAPSI scores were obtained for visits over time and compared between treatment groups at week 16, using a mixed-effect model for repeated measures, with study, visit, treatment-by-visit interaction, and baseline value as fixed effects, and repeated measures of visits (nested within patient).
Nominal P values are presented without adjustment for multiplicity of testing. Descriptive statistics are presented for the number of affected nails by visit up to week 52.
RESULTS
Patients
Of the 1859 patients who received treatment in OPT Pivotal 1 and 2, 1196 (64%) had nail psoriasis at baseline and were included in this analysis. Demographics and baseline characteristics were similar across treatment groups (Table I) . At baseline, patients had an average of 7 affected fingernails, and mean NAPSI score ranged from 26.9 to 27.3 across groups. Approximately one-quarter of patients with nail psoriasis reported a medical history of PsA.
Improvement in nail psoriasis severity
Visible improvements in the severity of nail psoriasis with tofacitinib treatment can be observed in Fig 1. Over 16 weeks, tofacitinib treatment resulted in reductions in pitting, onycholysis, subungual hyperkeratosis, and discoloration.
NAPSI score
At week 16, a significantly higher proportion of patients who received either tofacitinib 5 mg or 10 mg twice daily achieved NAPSI50, NAPSI75, and NAPSI100, compared with those who received placebo (all P \ .05; Fig 2) . Rates of complete clearance (NAPSI100) at week 16 were 10.3% (50/487) and 18.2% (87/476) with tofacitinib 5 mg and tofacitinib 10 mg twice daily, respectively, compared with 5.1% (12/233) with placebo. The proportions of patients achieving NAPSI50, NAPSI75, and NAPSI100 continued to increase from week 16 to week 28 and were largely maintained to week 52 with both tofacitinib doses (Fig 3) . For patients who advanced from placebo to tofacitinib at week 16, improvements in NAPSI50, NAPSI75, and NAPSI100 were observed on tofacitinib initiation, and, by week 52, response rates were similar to those of patients who had received active treatment throughout.
Baseline NAPSI scores were similar across treatment groups between patients with and those without PsA at baseline (Supplemental Table I ; available at http://www.jaad.org). Comparison of patients with and without PsA at baseline showed slightly higher proportions of patients without PsA achieving NAPSI50, NAPSI75, and NAPSI100 at week 16 for tofacitinib 10 mg twice daily and placebo but no consistent trend with tofacitinib 5 mg twice daily. Table I ).
The LS mean (standard error [SE]) change from baseline in NAPSI score at week 16 was significantly greater for both tofacitinib 5 mg twice daily (À7.9 [0.6]) and tofacitinib 10 mg twice daily (À10.5 [0.6]), compared with placebo (À0.4 [0.9]; both P \ .0001; Fig 4, A) . Percentage changes from baseline in NAPSI score at week 16 were also greater for both tofacitinib 5 mg twice daily (À16.5 [5.4] ) and tofacitinib 10 mg twice daily (À34.3 [3.9] ) compared with placebo (33.8 [17.0] ; Fig 4, C) . Improvements in NAPSI score from baseline continued to week 28 and were then maintained to week 52 for both tofacitinib doses (Fig 4, B and C) . Patients who advanced from placebo to tofacitinib at week 16 achieved 
Number of nails affected by psoriasis
The mean number of nails affected by psoriasis decreased over time to week 52 with both doses of tofacitinib (Fig 5) . For patients receiving tofacitinib 5 mg and tofacitinib 10 mg twice daily, the mean (SE) number of affected nails was 7.3 (0.1) and 7.3 (0.1), respectively, at baseline, decreasing to 3.5 (0.3) and 2.7 (0.2) at week 52.
DISCUSSION
This post hoc analysis evaluated the efficacy of tofacitinib, an oral JAK inhibitor, in treating nail psoriasis in patients with moderate-to-severe plaque psoriasis with nail involvement who had participated in the phase 3 OPT Pivotal 1 and OPT Pivotal 2 studies. The majority of the patients in the OPT Pivotal studies ([60%) had nail psoriasis at baseline consistent with the severity of disease. The relatively high baseline NAPSI score (;27) and number of affected nails (7/10) indicated that this study population had moderate-to-severe nail psoriasis at baseline. In addition, almost a quarter of patients with nail psoriasis also reported PsA at baseline, which is in line with current prevalence data for PsA in this ''at-risk'' population. 15, 16 Treatment with tofacitinib 5 mg and tofacitinib 10 mg twice daily led to significant improvements in nail psoriasis versus placebo at week 16. Improvements continued beyond week 16 up to week 28 and were then maintained up to week 52. At week 16, 10% and 18% of patients who received tofacitinib 5 mg and tofacitinib 10 mg twice daily, respectively, achieved complete clearance of nail psoriasis (NAPSI100), which increased to 16% and 29% by week 52.
The significant improvements in NAPSI scores by week 16 are consistent with the skin responses observed in OPT Pivotal 1 and 2 13 and are of interest, considering that nails tend to respond to therapy more slowly than skin. 10 By week 16, nail growth of only 1.4 cm would be expected, based on an average growth rate of 0.35 cm per month. 17 These improvements therefore suggest that tofacitinib had beneficial effects on the existing nail matrix and bed, not merely on new nail growth. Treatment effects on the nail bed often appear earlier than effects on the nail matrix, 18 and therefore improvement in psoriasis in the nail bed in particular may underlie these early clinical signs of efficacy.
Given the association between the presence of nail psoriasis and PsA, 8, 9 the effect of tofacitinib on nail psoriasis in patients with and without PsA at baseline was assessed. Although at week 16, a greater proportion of patients without PsA who received tofacitinib 10 mg twice daily and placebo achieved NAPSI50, NAPSI75, and NAPSI100 versus those with PsA, no consistent trend was observed Nominal P values are presented without adjustment for multiplicity of testing. BID, Twice daily; FAS, full analysis set; NAPSI, Nail Psoriasis Severity Index; NAPSI50, 50% reduction from baseline in NAPSI score; NAPSI75, 75% reduction from baseline in NAPSI score; NAPSI100, 100% reduction from baseline in NAPSI score; NRI, nonresponder imputation; SE, standard error.
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Fig 3.
Proportion of patients with nail psoriasis achieving (A) NAPSI50, (B) NAPSI75, and (C) NAPSI100 at all visits to week 52 (FAS, NRI). Dashed line at week 16 indicates the point at which patients in the placebo group were re-randomized to tofacitinib 5 mg or tofacitinib 10 mg BID. Dotted line at week 28 indicates the point at which treatment was discontinued in patients who did not achieve PASI75 or PGA response. BID, Twice daily; FAS, full analysis set; NAPSI, Nail Psoriasis Severity Index; NAPSI50, 50% reduction from baseline in NAPSI score; NAPSI75, 75% reduction from baseline in NAPSI score; NAPSI100, 100% reduction from baseline in NAPSI score; NRI, nonresponder imputation; PASI75, 75% reduction from baseline in Psoriasis Area and Severity Index score; PGA, Physician's Global Assessment; SE, standard error. . Dashed line at week 16 indicates the point at which patients in the placebo group were re-randomized to tofacitinib 5 mg or tofacitinib 10 mg BID. Dotted line at week 28 indicates the point at which treatment was discontinued in patients who did not achieve PASI75 or PGA response. Nominal P values are presented without adjustment for multiplicity of testing. BID, Twice daily; FAS, full analysis set; LS, least squares; NAPSI, Nail Psoriasis Severity Index; PASI75, 75% reduction from baseline in Psoriasis Area and Severity Index score; PGA, Physician's Global Assessment; SE, standard error.
J AM ACAD DERMATOL VOLUME 77, NUMBER 1 with tofacitinib 5 mg twice daily. By week 52, NAPSI response rates were generally higher across treatment groups in patients without PsA; however, these differences were numerically small, and the smaller number of patients with PsA compared with those without precludes any definitive conclusion regarding whether tofacitinib is more effective in the long term in treating nail psoriasis in patients without PsA. In addition, these data should be interpreted with caution because PsA was determined on the basis of patient reports at baseline only and was not formally assessed in the Pivotal studies, and, although potential differences were observed, no formal statistical comparison was made.
In the absence of head-to-head studies, it is difficult to compare efficacy for nail psoriasis between treatments because of variations in the definition and severity of nail psoriasis, patient population, time of assessment, and measurement tools used between studies. In general, over a period of 52 weeks, tofacitinib 5 mg and tofacitinib 10 mg twice daily provided greater improvement from baseline in NAPSI score (66% and 75% decrease from baseline NAPSI score, respectively) compared with the conventional systemic therapies of acitretin (41% decrease at week 26), 19 methotrexate (48% decrease at week 52), 20 and cyclosporine (37-47% decrease at week 24 or week 12, respectively). 21, 22 However, the quality and number of studies in systemic therapies are generally low, and therefore these comparisons should be made with caution, particularly given the different time scales, because improvements in nail psoriasis may take longer to observe compared with skin symptoms. Over a period of 52 weeks, tofacitinib appears to have efficacy in treating nail psoriasis within the range reported in a recent systematic literature review of biologic psoriasis therapies. 23 Across studies, decreases from baseline in NAPSI scores of 54% to 87% have been reported for adalimumab (reported at week 48), 51% to 92% for etanercept (week 54 or week 48), 40% to 95% for infliximab (week 36 or week 48), 79% for ixekizumab (week 48), and 57% to 97% for ustekinumab (week 36 or week 40). 23 It must be acknowledged that some limitations of the NAPSI have been raised with regard to its complexity and how well it correlates with patient-reported outcomes. 24, 25 In addition, the NAPSI only measures the extent of nail involvement and does not include items to assess the severity of disease. Validated instruments assessing the impact of nail psoriasis on the patient would also be of value. A limitation of the study design was the protocol-mandated discontinuation of patients who did not achieve PASI75 or PGA response at week 28, which did not take into account efficacy for nail psoriasis. A final limitation was that the analyses presented here were post hoc and therefore subject to the inevitable bias of this approach.
Tofacitinib had a manageable safety profile in the OPT Pivotal studies. 13, 26 Adverse event rates appeared to be generally similar across groups, Mean number of affected nails over time to week 52 (FAS, observed cases). Dashed line at week 16 indicates the point at which patients in the placebo group were re-randomized to tofacitinib 5 mg or tofacitinib 10 mg BID. Dotted line at week 28 indicates the point at which treatment was discontinued in patients who did not achieve PASI75 or PGA response. BID, Twice daily; FAS, full analysis set; PASI75, 75% reduction from baseline in Psoriasis Area and Severity Index score; PGA, Physician's Global Assessment; SE, standard error.
with low rates of serious adverse events, infections, malignancies, and discontinuations. Incidence rates of adverse events were generally consistent over time. Changes in laboratory parameters were not typically associated with clinical symptoms and did not appear to represent significant clinical safety risks.
In conclusion, we have demonstrated that tofacitinib 5 mg and tofacitinib 10 mg twice daily provided significant improvements in nail psoriasis versus placebo at week 16, with improvements sustained up to 52 weeks.
Supplemental Table I . Proportion of patients with nail psoriasis, with and without PsA at baseline, achieving NAPSI50, NAPSI75, and NAPSI100 at week 16 and week 52: Full analysis set, non-responder imputation Baseline NAPSI score, mean (SE) NAPSI50, n (%) NAPSI75, n (%) NAPSI100, n (%) BID, Twice daily; NAPSI, Nail Psoriasis Severity Index; NAPSI50, 50% reduction from baseline in NAPSI score; NAPSI75, 75% reduction from baseline in NAPSI score; NAPSI100, 100% reduction from baseline in NAPSI score; PsA, psoriatic arthritis; SE, standard error.
